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Open Forum Infectious Diseases
MAJOR ARTICLE

The Impact of Multidrug-Resistant Organisms on
Outcomes in Patients With Diabetic Foot Infections
Oryan Henig,1,2,a Jason M. Pogue,3,4 Emily Martin,5 Umar Hayat,6 Mahmoud Ja’ara,6 Paul E. Kilgore,7 Raymond Cha,7 Sorab Dhar,8 and Keith S. Kaye1
1
Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA, 2Division of Infectious Diseases, Rambam Health Care
Campus, Haifa, Israel, 3Department of Pharmacy Services, Sinai-Grace Hospital, Detroit Medical Center, Detroit, Michigan, USA, 4School of Medicine, Wayne State University, Detroit, Michigan,
USA, 5Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA, 6Department of Internal Medicine, Detroit Medical Center, Detroit, Michigan,
USA, 7Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA, and 8Division of Infectious Diseases, Detroit Medical Center, Wayne State
University, Detroit, Michigan, USA

Background. Multidrug-resistant organisms (MDROs) are important diabetic foot infection (DFI) pathogens. This study evaluated the impact of DFIs associated with MDRO pathogens (DFI-MDRO) on clinical outcomes.
Methods. Adults admitted to Detroit Medical Center from January 2012 to December 2015 with culture-positive DFI were
included. Associations between outcomes and DFI-MDRO (evaluated as a single group that included methicillin-resistant
Staphylococcus aureus [MRSA], vancomycin-resistant enterococci, Enterobacteriaceae resistant to third-generation cephalosporin
[3GCR-EC], Acinetobacter baumannii, and Pseudomonas aeruginosa) were analyzed. Outcomes included above- and below-knee
lower extremity amputation (LEA), readmissions, and mortality within a year after DFI. A propensity score predicting the likelihood
of having DFI-MDRO was computed by comparing patients with DFI-MDRO with patients with DFI with non-MDRO pathogens
(DFI-non-MDRO). Using conditional logistic regression, DFI-MDRO was analyzed as an independent variable after patients in the
MDRO and non-MDRO groups were matched by propensity score.
Results. Six hundred forty-eight patients were included, with a mean age ± SD of 58.4 ± 13.7. Most patients in the cohort presented with chronic infection (75%). DFI-MDRO occurred in greater than one-half of the cohort (n = 364, 56%), and MRSA was
the most common MDRO (n = 224, 62% of the DFI-MDRO group). In propensity-matched analyses, DFI-MDRO was not associated with 1-year LEA or readmissions, but was associated with recurrent DFI episodes (odds ratio, 2.1; 95% confidence interval,
1.38–3.21).
Conclusions. DFI-MDRO was associated with a 2-fold increased risk of recurrent DFI compared with patients with
DFI-non-MDRO.
Keywords. diabetic foot infection; multidrug-resistant organisms.
Among patients with diabetes, 10%–25% will develop diabetic
foot ulcer (DFU) throughout their lives [1]. Sixty percent of
DFUs may become infected, leading to a diabetic foot infection (DFI) [2]. Diabetic foot complications are the leading
cause of hospitalization among patients with diabetes and are
associated with an increased risk of lower limb amputation
[2]. Other consequences of DFI include impaired mobility,
impaired quality of life, and depression [3, 4]. In addition to
the associated morbidity, DFI substantially increases health
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care costs, comprising up to 30% of the excess medical costs of
patients with diabetes [3].
Multidrug-resistant organisms (MDROs) are common
pathogens in DFI patients [5], due in part to frequent health
care exposures and repeated courses of antibiotic treatment.
The growing prevalence of MDROs associated with DFI limits
antibiotic choices and sometimes leads to suboptimal therapy
[6–8]. Due to this increased MDRO prevalence and the importance of early effective antimicrobial therapy, current national
guidelines recommend the empiric use of broad-spectrum antibiotics in patients who have moderate to severe DFI [6].
Although some data suggest that infections due to MDROs
result in worse outcomes more frequently than susceptible isolates [7, 9, 10], evidence pertaining to the impact of MDROs on
DFI is conflicting. In several studies, DFI due to MRSA has been
associated with poor ulcer healing [11], treatment failure [7],
readmission to the hospital [12], and increased mortality [13],
and MDROs have been associated with poor glycemic control
[8]. However, in other studies of DFI, MDROs were not associated with worse clinical outcomes [14, 15]. In addition, the
association between DFIs due to MDROs and lower extremity
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amputation (LEA) remains unclear. The objective of this study
was to evaluate the impact of DFI associated with MDROs on
clinical outcomes, including recurrent DFI, hospital readmission, and LEA.
METHODS
Study Setting and Cohort Description

The cohort included all adult patients with DFI who were admitted to the Detroit Medical Center (DMC; a metropolitan
health system including 4 acute care hospitals and 1 rehabilitation center) between January 2012 and December 2015
with positive cultures from diabetic foot lesions. Potential
DFI cases were identified based on having an International
Classification of Diseases, 9th revision (ICD-9), code for diabetes mellitus and for skin and soft tissue infection (SSTI) and/
or osteomyelitis (ICD-9 codes that were used were 249, 250,
680–686, 730). Subsequently admission and discharge notes,
as well as podiatry and infectious diseases consult notes, were
reviewed, and actual DFI diagnosis was confirmed by documented signs and symptoms of infection (erythema, warmth,
pus drainage, and/or fetid odor). Patients were excluded from
the study if any of the following were met: (1) infection status
of the ulcer could not be determined from chart review or infection was ruled out by care providers, (2) the SSTI was not
related to the foot, (3) infection following a fracture and/or a
surgical site infection was present, (4) cultures grew organisms that were considered to be contaminants (eg, coagulasenegative Staphylococcus spp. and/or Corynebacterium spp.
that grew from only a single set of cultures, or grew only in a
nonsterile culture) [6, 16]. The institutional review boards of
Wayne State University and the DMC approved this study for
waiver of informed consent.
Definitions

The date of DFI diagnosis was defined as the day of the first
positive culture for a DFI episode. An index episode was defined as the first DFI episode over the study period associated
with a multidrug-resistant organism (DFI-MDRO), and if a
subject had no DFI episode with an MDRO during the entire
study period, then the first DFI episode during the study period
was considered to be the index episode (DFI-non-MDRO).
Subjects contributed only 1 unique index episode to the cohort.
All DFI episodes for all subjects were captured throughout the
study period both before and after the index episode.
For the purposes of these analyses MDROs included
methicillin-resistant
Staphylococcus
aureus
(MRSA),
vancomycin-resistant Enterococcus (VRE), Enterobacteriaceaeresistant third-generation cephalosporins (3GCR-EC) and/or
carbapenem, and all antimicrobial susceptibility phenotypes
of Pseudomonas aeruginosa, Acinetobacter baumannii, and
Stenotrophomonas maltophilia.
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Outcome Definitions

Recurrent DFIs were defined as a DFI episode that occurred
during the time period spanning from 14 days after the index
episode until 1 year later. Lower extremity amputation (LEA)
included below-knee amputation or above-knee amputation
that occurred during admission for the index episode or within
1 year of follow-up. In addition, less extensive amputations
(“other amputations”) were captured during index admission
and the 1-year follow-up period. Readmission was defined as
any admission within 1 year of the index episode. Mortality was
captured within 1 year of an index episode. Length of stay for
the index admission was calculated from the day of DFI diagnosis to the day of discharge.
Study Variables

Data pertaining to demographics, source of admission (home,
long-term care facilities [LTCFs], transfer from another hospital), hospitalization within the past 90 days, comorbidities
including the Charlson comorbidity index, insurance type, admission unit, and severity of sepsis at time of index DFI episode
diagnosis [17] (determined using the most extreme values of
the Systemic Inflammatory Response Syndrome Score within
2 days of DFI diagnosis) were collected. Intensive care unit
(ICU) admission and mechanical ventilation and acute hemodialysis status were captured within 7 days after the date of the
DFI diagnosis. Variables associated with diabetes status that
were collected included highest HbA1C value within 3 months
before the DFI episode, presence of diabetes-related end-organ
damage, and ankle-brachial index (ABI) values when available.
The depth of involvement of DFI was determined based on providers’ documentation and radiology and pathology findings
and was classified as superficial, deep tissue, or bone involvement. Definitive therapy was defined as the antimicrobial treatment given following release of microbiology results, including
susceptibility testing. Duration of antibiotic treatment was categorized into “inpatient duration of therapy” and “total duration of therapy.” The latter included inpatient administration as
well as outpatient treatment, which was determined according
to discharge notes and prescriptions. Antimicrobial treatment
information in the 3 months before DFI diagnosis was also abstracted from the medical record.
Surgical interventions were recorded for all DFI episodes,
including bedside debridement, operating room (OR) debridement, and amputations (including LEA and less extensive
amputations).
Microbiology

Microbiology data for each patient included cultures obtained
from DFI lesions and were classified as swab cultures obtained
at the bedside, tissue cultures obtained at the bedside, swab cultures obtained in the OR, tissue cultures obtained in the OR,
and bone cultures obtained in the OR. For a given episode, all

cultures from the DFI lesion that were obtained within a period
of 14 days after the index episode date were considered to be
part of the index DFI episode. A polymicrobial episode was defined as an episode during which more than 1 pathogen was
recovered.
Data Analysis

Participant characteristics among the cohort and prevalence of
MDROs were calculated using means and SDs, as well as medians with interquartile range (IQRs) where appropriate.
Baseline characteristics of subjects with DFI-MDRO were
compared with subjects with DFI-non-MDRO using the Fisher
exact test. Similarly, subjects with a specific MDRO were compared with subjects without that specific MDRO (eg, subjects
with DFI associated with P. aeruginosa [DFI-PA] were compared with subjects without PA [DFI-non-PA]).
A multivariable model predicting DFI-MDRO was developed
and is described elsewhere [18]. In brief, variables with a P value
of <.2 in the bivariable analysis were included in a candidate
logistic regression model. Backwards stepwise regression was
performed to identify independent predictors for DFI-MDRO.
Variables predicting DFI-MDRO were then used to compute
a propensity score [18]. The independent association between
Table 1.

DFI-MDRO and each outcome was determined by conditional
logistic regression models with frequency-matching by strata of
propensity score between DFI-MDRO and DFI-non-MDRO.
Similar analytic methodology was used to identify the impact
of each individual MDRO on outcomes. For example, a propensity score for having DFI associated with PA (DFI-PA) was computed by comparing subjects with DFI-PA with subjects who
had DFI without PA (DFI-non-PA), and propensity-matched
conditional logistic regression was conducted for each outcome.
All P values were 2-sided.
RESULTS

Between 2012 and 2015, 1210 subjects with possible DFI were
screened. Five hundred sixty-two patients were excluded for 1
or more of the following reasons: absence of positive cultures,
skin and soft tissue infection located in an area other than the
foot, documentation of noninfected diabetic foot ulcer, or isolation of coagulase-negative Staphylococci or Corynobacterium
spp. from a single nonsterile culture.
Six hundred forty-eight unique subjects were determined to
have DFI and were included in the study cohort (Table 1). The
mean age was 58.4 ± 13.7, 64% were male, and 73% were African
American. The median Charlson comorbidity index (IQR) was

Description of the Cohort and Outcomes of Patients With DFI-MDRO Compared With Patients With DFI-Non-MDRO
DFI-MDRO
(n = 364)

DFI-Non-MDRO
(n = 284)

Crude OR (95% CI)a

59.2 ± 13.8

57.4 ± 13.6

P = .09

135 (37.1)

96 (33.8)

P = .41

74 (21.1)

36 (13.2)

1.32 (0.81–2.16)

141 (38.7)

56 (19.7)

1.53 (0.99–2.38)

40 (11.0)

18 (6.3)

1.48 (0.74–2.95)

Adjusted OR (95% CI)

Demography and comorbid conditions
Age, mean ± SD, y
Gender (female), No. (%)
Bedridden status, No. (%)
Recent hospitalization, No. (%)
LTCF residence,
No. (%)
Charlson comorbidity index,
median (IQR)
CKD, No. (%)

5 (3 to 7)

4 (3 to 6)

P < .001

118 (32.4)

65 (22.9)

Retinopathy, No. (%)

68 (18.7)

49 (17.3)

1.10 (0.73–1.656)

Neuropathy, No. (%)

308 (84.6)

227 (79.9)

1.38 (0.92–2.07)

PVD, No. (%)
ABI (n = 231), median (IQR)
HbA1C (n = 531), mean ± SD

1.48 (1.00–2.18)

270 (74.2)

172 (60.6)

1.45 (1.00–2.09)

0.99 (0.69 to 1.20)

0.99 (0.67 to 1.17)

P = .36

8.8 ± 2.5

9.4 ± 2.8

P = .01

Management
Inpatient duration of treatment, median (IQR)

9 (6 to 15)

8 (5 to 13)

P = .06

Total duration of treatment, median (IQR)

20 (13 to 42)

16 (11 to 34)

P = .002

Outcomes (within 1 y)
Recurrent DFI, No. (%)

90 (24.7)

35 (12.3)

2.34 (1.53–3.58)

2.1 (1.38–3.21)

LEA, No. (%)

59 (16.2)

29 (10.2)

1.70 (1.06–2.73)

1.25 (0.74–2.13)

145 (51.1)

0.84 (0.62–1.15)

0.79 (0.96–1.35)

Less extensive amputation, No. (%)
Length of stay, median (IQR), d
Readmissions, No. (%)
Mortality, No. (%)

170 (46.7)
9 (6 to 13)

7 (5 to 11)

234 (64.3)

157 (55.3)

23 (7.6)

13 (5.6)

P < .001
1.46 (1.06–2.0)

1.13 (0.80–1.61)

1.38 (0.68–2.78)

0.95 (0.43–2.09)

Abbreviations: ABI, ankle-brachial index; CI, confidence interval; CKD, chronic kidney disease; HbA1C, hemoglobin A1C; LEA, lower extremity amputation; LTCF, long-term care facility;
MDRO, multidrug-resistant organism; OR, odds ratio; PVD, peripheral vascular disorder.
a

For continuous variables, P values are presented instead of odds ratios (ie, age, Charlson score, ABI, HbA1C, length of stay, duration of treatment).
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5 (3 to 6), and 83% had peripheral neuropathy. Twenty-five percent of the patients presented with either sepsis or septic shock.
The majority of patients (63%) had bone involvement with their
infection.
Three hundred sixty-four patients (56%) had DFI with at least
1 MDRO (DFI-MDRO). The most common MDRO was MRSA
(n = 224 patients, 62% of patients who had DFI-MDRO), followed by P. aeruginosa (n = 94, 26%), 3GCR-EC (n = 51, 14%),
and VRE (n = 52, 14%). Most cultures (n = 457, 72%) were
polymicrobial and were obtained in the OR (70%), including
bone biopsies. One hundred sixty-four subjects had anaerobic
organisms recovered from their DFI. Ninety patients (13.9%)
had DFI with more than 1 MDRO, and 20 (3.1%) had DFI with
3 or more MDROs (18 had 3 MDROs, and 2 had 4 MDROs).
The most common MDROs recovered from polymicrobial cultures were P. aeruginosa (n = 56) and MRSA (n = 26).
In bivariable analysis, patients who had DFI-MDRO had
higher prevalence of comorbid conditions were more likely to
be admitted from long-term care facilities, to be bedridden,
and to have a history of recent hospitalization compared with
patients with DFI-non-MDRO (Table 1). In addition, patients
with DFI-MDRO had a higher frequency of prior use of an antibiotic within the previous 3 months compared with patients
with DFI-non-MDRO (168, 46.2%, vs 71, 25%; P < .001).

Eighty-eight (14%) underwent lower limb amputation, 391
(60%) were readmitted, and 36 (7%) patients died within 1 year.

Management

Outcomes Among Patients With DFI-PA

The median duration of inpatient antibiotic treatment (IQR)
was 9 (6 to 14) days, and the median duration of total antibiotic treatment (IQR) was 18 (12 to 40) days. Patients with
DFI-MDRO were treated with longer antibiotic durations than
patients with DFI-non-MDRO (median of total duration [IQR],
20 [13 to 42] days and 16 [11 to 34] days, respectively; P = .002).
Overall, 546 subjects (85%) received treatment that was considered to be active against all of the pathogens associated with
DFI, and the median time between the day of DFI diagnosis
and receiving active therapy (IQR) was 0 (−1 to 1) days. Among
subjects who had DFI-MDRO, 22% (n = 79) received definitive therapy that was not active against all pathogens, compared with 8% (n = 23) of DFI-non-MDRO subjects (P < .001).
Among patients with DFI-VRE, VRE was not treated in 44% of
cases (n = 23/52); among patients with DFI-PA, P. aeruginosa
was not treated in 11% of cases (n = 10/94); and among patients
with DFI-3GCR-EC, the resistant Enterobacteriaceae were not
treated in 16% of cases (n = 9/51).
Overall, surgical debridement was performed in 89.1% of the
patients (574), and 323 (49%) had an amputation during their
admission.
Description of Outcomes in the Cohort

One hundred twenty-five patients (19.3%) had recurrent
DFI episodes within 1 year of the index episode (Table 1).
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Outcomes Among Patients With DFI-MDRO vs Non-MDRO

In bivariable analyses, patients with DFI-MDRO were more
likely to have recurrent DFI (Operating room [OpR], 2.34; 95%
confidence interval [CI], 1.53–3.58), LEA occurring within
1 year (OR, 1.7; 95% CI, 1.06–2.7), readmission within 1 year
(OR, 1.46; 95% CI, 1.06–2.0), and longer duration of hospitalization during index admission (median duration [IQR], 9
[6 to 13] days compared with 7 [5 to 11] days) compared with
DFI-non-MDRO (P < .001) (Table 1). There was no difference
in frequency of less extensive amputations or in all-cause mortality between the groups. A propensity score for DFI-MDRO
included the following predictors for DFI-MDRO: admission
from an LTCF, prior hospitalization within the last 90 days,
chronic kidney disease, bedridden status, peripheral vascular
disease, prior debridement within the last year, use of any
antibiotic within the last 3 months, and prior diabetic foot
ulcer with an MDRO. When controlling for differences between the 2 groups in a propensity-matched model (n = 583)
(Supplementary Table 1), DFI-MDRO was an independent predictor for recurrent DFI (OR, 2.02; 95% CI, 1.27–3.22), but not
for LEA or any other outcomes.

In bivariate analysis, patients with DFI-PA (as compared with
patients without DFI-PA) had significantly higher risk for
higher risk for LEA occurring within 1 year (OR, 2.09; 95% CI,
1.21–3.62) (Table 2). The duration of hospitalization was longer
for patients with DFI-PA compared with DFI-non-PA (median
duration [IQR], 10 [6 to 15] days compared with 8 [5 to 12]
days; P = .009). The propensity score for DFI-PA included
chronic kidney disease, peripheral vascular disease, admission
from an LTCF, prior hospitalization within the last 90 days,
bedridden status, prior diabetic foot ulcer with PA, and prior
use of cefepime or fluoroquinolones within the past 3 months.
However, in a propensity score–matched model (n = 480)
(Supplementary Table 2), DFI-PA was not associated with any
of the outcomes.
Outcomes Among Patient With DFI-VRE

DFI-VRE was associated with a higher prevalence of recurrent
DFI (OR, 2.19; 95% CI, 1.19–4.06) and LEA within 1 year (OR,
2.05; 95% CI, 1.03–4.09) (Table 2). The propensity score for
DFI-VRE included chronic kidney disease, peripheral vascular
disease, prior diabetic foot ulcer with VRE, prior hospitalization within the past 90 days, prior debridement, and prior use of
vancomycin within the past 3 months. In a propensity-matched
analysis (n = 437) (Supplementary Table 4), DFI-VRE was associated with a >2-fold increased risk of having recurrent DFI

For continuous variables, P values are presented instead of odds ratios (ie, age, Charlson score, ankle-brachial index, hemoglobin A1C, length of stay, duration of treatment).

Outcomes Among Patients With DFI-3GCR-EC

a

Abbreviations: 3GCR-EC, third-generation resistant Enterobacteriaceae; CI, confidence interval; DFI, diabetic foot infection; LEA, lower extremity amputation; LOS, length of stay; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant
Staphylococcal aureus; OR, odds ratio; PA, Pseudomonas aeruginosa; VRE, vancomycin-resistant Enterococcus.

0.63
(0.29–1.36)
0.63
(0.29–
1.36)
27 (7.7)
9 (5)
1.01
(0.32–3.17)
32 (6.5)
8 (19.1)
7 (8.3)
Mortality
(n = 535),
No. (%)

36 (6.7)

29 (6.4)

1.32
(0.56–3.12)

0.65
(0.25–1.73)

28 (5.7)

3.90
(1.65–9.21)

1.02
(0.22–4.72)

4 (9.1)

1.43
(0.48–
4.25)

5.5
(0.3 to 11)
P = .06
8 (5 to 12)
8 (6 to 12)
−1.7
(−10.6 to 8)
P = .98
8 (5 to 12)
7.5 (5 to
13.5)
6.6
(−5.3
to 20.2)
P < .001
11 (7 to 18)
10 (6 to 15)
Length of stay,
median
(IQR), d

8 (5 to 12)

8 (5 to 12)

0.009

4.5
(−3 to 12.7)

8 (5 to 12)

1.10
(0.78–1.53)
1.08
(0.78–
1.51)
138 (61.6)
353 (59.2)
32 (62.8)
391 (60.3)
Readmissions,
No. (%)

63 (67.0)

328 (59.2)

1.40
(0.88–2.22)

1.04
(0.62–1.74)

359 (60.1)

1.11
(0.62–2.01)

1.34
(0.54–3.31)

38 (73.1)

1.87
(0.99–
3.52)

1.42
(0.70–2.86)

253 (59.7)

0.92
(0.67–1.28)
0.89
(0.65–
1.24)
105
(46.9)
290
(48.7)
19
(37.3)
42
(44.7)
315
(48.6)
Less extensive
amputation,
No. (%)

273
(49.3)

0.83
(0.54–1.29)

1.09
(0.66–1.79)

296
(49.6)

0.60
(0.33–1.09)

1.11
(0.48–2.53)

25
(40.1)

0.98
(0.55–
1.72)

1.10
(0.59–2.05)

210
(49.5)

0.84
(0.52–1.35)
0.87
(0.54–
1.40)
28
(12.5)
76
(12.8)
17 (33.3)
21
(22.3)
88
(13.6)
LEA, No. (%)

67
(12.1)

2.09
(1.21–3.62)

1.59
(0.88–2.89)

71
(11.9)

3.70
(1.97–6.97)

2.28
(0.93–5.62)

12
(23.1)

2.05
(1.03–
4.09)

1.50
(0.72–3.09)

60
(14.2)

1.47
(0.99–2.18)
1.52
(1.02–
2.26)
72
(17.0)
53
(23.7)
2.57
(1.29–5.12)
108
(18.1)

OR (95% CI)

1.66
(0.87–3.17)
111
(18.6)
14
(27.5)
1.55
(0.88–2.74)
1.54
(0.92–2.56)
101
(18.3)
24 (25.5)
125
(19.3)
Recurrent DFI

a

2.95
(1.25–6.98)

17
(32.7)

2.19
(1.19–
4.06)

Adjusted
HR
(95% CI)
ORa
(95%
CI)
DFI-NonMRSA (n =
424)
DFIMRSA
(n = 224)
Adjusted
HR
(95% CI)
ORa (95%
CI)
Non-VRE
(n = 596)
VRE
(n = 52)
Adjusted
HR
(95% CI)
Non3GCR-EC
(n = 597)
3GCR-EC
(n = 51)
Adjusted
HR
(95% CI)
ORa
(95% CI)
Non-PA
(n = 554)
PA
(n = 94)
Entire
Cohort

Outcomes of DFI With Individual MDRO (Within 1 Year)
Table 2.

(OR, 2.57; 95% CI, 1.29–5.12) but was not associated with other
outcomes.

Patients who had DFI-3GCR-EC had higher risk of LEA
occurring within 1 year (OR, 3.23; 95% CI, 1.66–6.28) and had
longer duration of hospitalization (median duration [IQR],
11 [7 to 18] days) compared with patients who had DFI-non3GCR-EC (median duration [IQR], 8 [5 to 12] days; P < .001)
(Table 2). In addition, the mortality rate was higher in the DFI3GCR-EC group (n = 8/51, 19%, vs n = 28/597, 5.7%; OR, 3.9;
95% CI, 1.65–9.21). The propensity score for DFI-3GCR-EC
included peripheral vascular disease, congestive heart failure,
dementia, admission from an LTCF, bedridden status, prior diabetic foot ulcer with 3GCR-EC, prior hospitalization within
the past 90 days, prior use of third-generation cephalosporin,
and receipt of cefepime or a beta-lactam/beta-lactamase inhibitor within the past 3 months. In propensity-matched analyses
(n = 438) (Supplementary Table 3), DFI-3GCR-EC was associated with recurrent DFI within 1 year (OR, 2.12; 95% CI, 1.00–
4.51), but not with other outcomes.
Outcomes Among Patients With DFI-MRSA

In bivariable analysis, patients with DFI-MRSA were at higher
risk for recurrent DFI within 1 year compared with patients
with DFI-non-MRSA (OR, 1.52; 95% CI, 1.02–2.26) (Table 2).
The propensity score for DFI-MRSA included diabetic neuropathy, dementia, bedridden status, prior diabetic foot ulcer with
MRSA, prior debridement, and prior use of beta-lactam within
the past 3 months.
In a propensity-matched model (n = 452) (Supplementary
Table 5), there was no association between DFI-MRSA and any
of the outcomes. However, there was a trend toward significantly higher likelihood of having recurrent DFI within 1 year
(OR, 1.47; 95% CI, 0.99–2.18).
DISCUSSION

In this cohort of poorly controlled diabetic patients with DFI
and a high degree of comorbidity, almost 60% of the patients
had infection involving at least 1 MDR pathogen, and in onequarter of DFI-MDRO cases, more than 1 MDRO was recovered.
MRSA was the most common MDRO recovered, followed
by P. aeruginosa, VRE, and third-generation cephalosporinresistant Enterobacteriaceae.
Patients who had DFI involving MDRO pathogens had a
>2-fold increased risk for having recurrent DFI and a prolonged
duration of hospitalization during their index admission, compared with patients who had DFI involving only susceptible
pathogens. Similar associations were observed for each individual type of MDRO. Interestingly, although other outcomes,
such as LEA, readmission, and mortality, were more prevalent in patients who had DFI-MDRO compared with patients
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who had DFI-non-MDRO, none of these outcomes was independently associated with DFI-MDRO in propensity-adjusted
analyses. Other studies have reported weak or no association
between MDRO and DFI outcomes [14, 19]. To our knowledge,
this is the largest study that has evaluated the impact of individual MDROs on LEA.
Several reasons may have explain the lack of an independent
association between MDRO and certain outcomes including
LEA, readmission, and mortality. First, the majority of the patients in both the DFI-MDRO and DFI-non-MDRO groups
had polymicrobial infections, with various combinations of
different types of pathogens. Nevertheless, in both of the study
groups, the majority of patients received therapy with in vitro
activity against all pathogens present (effective therapy) during
the index episode. Given that both groups received effective
therapy, any expected differences in DFI outcomes related to the
presence of MDROs may have been obviated. In instances where
therapy did not provide activity against all MDROs present, the
most common MDRO not treated was VRE. The role of VRE
as a true pathogen, particularly in the setting of polymicrobial
infection, is debatable [20]. Second, most of the patients who
were treated for DFI had chronic infection (only 25% of patients
in the cohort presented with signs and symptoms of sepsis or
septic shock). In the setting of chronic infection, factors such
as peripheral neuropathy and poor vascular supply may have a
greater impact on ulcer healing than the presence of MDROs.
Finally, surgical debridement and source control are critical
components of the effective management of DFI, and these associations are likely independent of MDRO status.
The frequency of MDROs in this cohort from metro Detroit
was extremely high (approaching 60%). This high frequency of
MDRO pathogens raises the question of whether, in some settings, empiric antibiotic regimens for DFI should include coverage for MDROs. Although MDROs were not independently
associated with some adverse outcomes including readmission,
LEA, and mortality, they were associated with recurrent DFI and
increased duration of hospitalization. Prospective controlled
studies are needed to better understand the role of broad-spectrum empiric antibiotic therapy that provides coverage against
MDROs in the management and clinical outcomes of patients
with DFI-MDRO.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
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